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 Abstract 
 Pituitary adenomas (PA) are common endo-
crine neoplasia, generally presenting as 
 sporadic diseases, with a multifactorial 
pathogenesis including somatic mutational 
events in cancer-related genes. However, 
genetic predisposition can currently be recog-
nized in >5% of affected patients, mostly 
involving the Multiple Endocrine Neoplasia 
type 1 ( MEN1 ) gene and the more recently 
identi fi ed Aryl hydrocarbon receptor 
Interacting Protein ( AIP ) gene, both being 
tumor-suppressor genes. Germline muta-
tions in the AIP gene can be observed in a 
FIPA (Familial Isolated Pituitary Adenoma) 
context, but also in a minority of young 
patients with an apparently sporadic disease. 
Although the role of AIP in the pathogenesis 
of PA remains largely unknown, it is known 
to be mainly expressed by somatototrophs, 
with a frequent loss of expression in most 
AIP-mutated PA and in invasive somatotro-
pinomas. The best characterized function of 
AIP is to stabilize the Aryl hydrocarbon 
Receptor, also known as the dioxin receptor, 
in the cytoplasm, but multiple interactions 
of AIP with other proteins involved in endo-
crine signalling and the regulation of cell 
cycle and apoptosis have been reported. In 
this chapter, current knowledge about the 
possible role of AhR and additional AIP-
related  proteins in pituitary tumorigenesis 
will be analysed. 
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 Introduction 
 Pituitary adenomas (PA) are among the most 
frequent endocrine tumors, with a clinical preva-
lence approaching 1/1,000 inhabitants in recent 
studies (Beckers  2010 ) . PA are typically benign, 
but extrasellar extension is frequent and invasive 
features towards surrounding structures (i.e., the 
dura, sellar bone, cavernous sinus) increase with 
tumor size. Malignant evolution is extremely rare 
and de fi ned by extra-pituitary dissemination. PA 
are classi fi ed into secreting and non-secreting 
according to the presence or absence, respec-
tively, of pituitary hormone hypersecretion. Their 
pathogenesis is multifactorial and, despite com-
mon monoclonality suggesting the presence of an 
initiating molecular event, they are usually spo-
radic, with a complex pathogenesis including 
genetic and epigenetic events and a variety of 
alterations in intra- and extra-cellular signalling 
(Asa and Ezzat  2009 ) . 
 Inherited genetic susceptibility is being 
increasingly recognized and is currently esti-
mated to involve at least 5% of PA patients. 
Arguments suggesting inherited susceptibility 
are: (1) the presence of extra-pituitary manifesta-
tions suggestive of a syndromic disease, namely 
the Multiple Endocrine Neoplasia type 1 syndrome 
(MEN1), which accounts for nearly 3% of PA, 
rarely the Carney’s complex (CNC) or McCune 
Albright syndrome (MAS), (2) the presence of an 
isolated familiarity for PA, which was  fi rst recog-
nized for patients with acromegaly (Isolated 
Familial Somatotropinoma – IFS), subsequently 
shown to potentially involve all PA phenotypes 
(Familial Isolated Pituitary Adenoma- FIPA) and 
also represents 2–3% of PA patients, (3) an early 
onset of the disease, especially in children and 
adolescents, who represent about only 10% of PA 
patients but are more likely to be syndromic or 
familial. We have recently reviewed the clinical 
presentation, molecular genetics and screening 
implications of the syndromic conditions cited 
hitherto (Jaffrain-Rea et al.  2010a ) and we will 
focus our attention on the most relevant aspects 
of the FIPA syndrome and on the potential patho-
genetic implications of the  Aryl hydrocarbon 
receptor Interacting  Protein (AIP) gene, which 
currently explains a signi fi cant subset of FIPA 
kindreds and has been involved in a minority of 
early onset PA with an apparently sporadic 
presentation. 
 Familial Isolated Pituitary Adenomas 
(FIPA), the  AIP Gene and the Expanding 
Spectrum of  AIP -Related Diseases 
 Familial tumors offer unique opportunities to 
characterize genes involved in their pathogenesis 
and, indirectly, in the normal physiology of the 
corresponding tissue. Familial forms of pituitary 
tumors occurring in association with hyperpara-
thyroidism and pancreas endocrine neoplasia 
have de fi ned the MEN1 syndrome and contrib-
uted to the identi fi cation of a disease locus in 
11q13, leading in 1997 to the identi fi cation of the 
MEN1 gene, a major tumor suppressor gene. As 
recently reviewed by Thakker  ( 2010 ) , hundreds 
of inactivating mutations of the MEN1 gene 
could then be identi fi ed in MEN1 kindreds, 
genetic mice models have further supported the 
role of the MEN1 gene in disease susceptibility, 
and the molecular mechanisms involved in 
MEN1-related tumorigenesis are being progres-
sively elucidated. Kindreds with isolated soma-
totropinomas (IFS) were already recognized to 
occur outside of the MEN1 syndrome and later 
con fi rmed to be unrelated to  MEN1 gene muta-
tions. Nonetheless, linkage to the 11q13 region 
could be established in some cases by Galdelha 
et al.  ( 1999 ) , with documented LOH in the cor-
responding tumors suggesting the presence of a 
second tumor suppressor gene in this region. 
Recently, two important publications have lead to 
signi fi cant progress in the elucidation of inher-
ited predisposition to PA linked to a new tumor 
suppressor gene in 11q13: (1) Vierimaa et al. 
 ( 2006 ) identi fi ed germline inactivating mutations 
of the  AIP gene in two large Finnish kindreds 
with GH/PRL-secreting PA and in an Italian IFS 
family; with somatic LOH in 11q13 being 
con fi rmed in the corresponding tumors, (2) Daly 
et al.  ( 2006 ) characterized 64 kindreds with 
Familial Isolated Pituitary Adenomas (FIPA) 
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collected internationally, comprising both 
homogenous and heterogeneous families – i.e. 
expressing a single or multiple PA phenotypes, 
respectively –, the homogenous somatotropi-
noma/IFS subgroup representing ~ 30% of the 
whole series. Soon after, the same group reported 
germline mutations in the  AIP gene in 15% of 
FIPA kindreds, and up to 50% of those with 
homogeneous somatotropinomas/IFS, respectively 
(Daly et al.  2007 ) . 
 Clinical Presentation of Patients 
with a Germline AIP Mutation 
 The great interest in  AIP as a new player in pitu-
itary tumorigenesis has lead to a number of 
genetic studies on FIPA and sporadic PA allow-
ing, within a 4 years period, to delineate the 
most common characteristics of  AIP mut patients 
and tumors, and to evaluate their therapeutic 
outcome. In a recent collaborative work collecting 
96  AIP mut patients worldwide (Daly et al.,  2010 ), 
60% cases occurred in a documented FIPA set-
ting and 40% were apparently sporadic, respec-
tively. Somatotropinomas were by far the most 
prevalent phenotype (~80%), followed by prolac-
tinomas (~15%), NFPA, and rare corticotrophino-
mas and thyreotrophinomas. The median age at 
diagnosis and at  fi rst symptoms were 23 and 18 
years overall, implying that half of the patients 
developed a symptomatic disease during child-
hood or adolescence. In this study, 75  AIP mut 
somatotropinomas were compared to 232  non-
AIP  mu t somatotropinomas con fi rmed genetically, 
providing  fi nal evidence that the presence of ger-
mline  AIP changes in acromegalics was associ-
ated with a much earlier age at diagnosis (20 
years earlier) and a more aggressive course of the 
disease. The early onset translated into an unusual 
rate of overt or incipient gigantism (32  vs 6% 
in control cases). A male predominance was 
observed (>60%) and all giant were males. 
Somatotropinomas in the  AIP  mut  group were typi-
cally macroadenomas (>90%) and, as compared 
with non- AIP  mut  somatotropinomas, they had 
signi fi cantly larger maximal tumor diameter. At 
diagnosis,  AIP  mut  acromegalics had higher median 
plasma GH levels and presented twice more fre-
quently with PRL hypersecretion than non- AIP  mut  
patients. Disease control in  AIP  mut  somatotropi-
nomas was also more dif fi cult to achieve, with a 
lower decrease in GH/IGF-1 on somatostatin 
analogues therapy and a more frequent need for 
multiple surgeries and/or radiotherapy. 
Prolactinomas in  AIP  mut  patients were also recog-
nized essentially in males (>75%), with a median 
age at diagnosis of 22 years, ~50% occurred in a 
familial setting and most were large and invasive, 
with an unusual rate of resistance to dopamine-
agonist therapy (50%). 
 Molecular Genetics of AIP 
 Oz fi rat and Korbonits  ( 2010 ) have reviewed 
nearly 50  AIP mutations identi fi ed so far by inter-
national cohorts, reported by the Finnish, Belgian 
and British groups and additional family case 
reports. Most mutations are distributed through 
the entire coding sequence (6 exons), 60–70% 
are truncating – with a similar frequency for non-
sense and frameshift mutations, followed by 
splice site mutations – and >20% are missense. 
The remaining alterations include large deletions 
and some changes of uncertain biological 
signi fi cance, such as rare polymorphisms and 
intron variants not expected to alter splicing. 
Promoter mutations have also been exceptionally 
reported. Some mutations have been encountered 
more frequently, such as  AIP Q14X - a founder muta-
tion in Finland-,  AIP R304X – the most frequently 
reported in Europe, with a partial founder effect 
in Italy -,  AIP R304Q – which further indicates codon 
304 as a hot mutational spot-,  AIP R271W , and 
 AIP R81X . Codon K241 may represent an additional 
hot spot, with both  AIP K241E and  AIP K241X changes 
being reported. 
 The penetrance of germline  AIP mutations is 
incomplete. In FIPA kindreds, due to a still limited 
knowledge on large  AIP mut kindreds, it is currently 
but imprecisely estimated around 30% (15–45%). 
Preliminary data on familial screening in appar-
ently sporadic patients indicate that  de novo ger-
mline  AIP mutations are very rare, but most  AIP mu t  
relatives are unaffected. At the moment,  AIP can 
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be therefore considered either as a FIPA gene, 
which can be inherited in a dominant manner with 
a variable but clinically relevant penetrance, or as 
a PAP gene, with a low penetrance. These views 
are not necessarily con fl icting since, similarly to 
disease severity, disease penetrance may vary 
 Fig. 21.1  AIP molecular interactions and related path-
ways. AIP is involved in multiple protein–protein interac-
tions and potential molecular pathways: (1) the transcription 
factor AhR (Aryl hydrocarbon Receptor, or dioxin receptor) 
is stabilized by AIP in a cytoplasmic AhR/AIP/hsp90/p23 
core complex; upon activation by exogenous AhR moves to 
the nucleus, heterodimerizes with Ah Receptor Nuclear 
Translocator (ARNT) and exerts direct transcriptional 
effects through Dioxin Responsive Elements (DRE) – acti-
vation by endogenous ligands (including cAMP) may elicit 
a different transcriptional response – (2) members of the ste-
roid receptor superfamily include the transcription factor 
PPAR a , the thyroid receptor TR b 1 and the glucocorticoid 
receptor, (3,4) Phosphodiesterases PDE2 and PDE4A5 are 
involved in the regulation of the cAMP concentration. 
cAMP is produced from ATP by the Adenyl Cyclase (AC), 
activates the Protein Kinase A (PKA) by binding its regula-
tory subunits (RR) and releasing its catalytic subunits (CC); 
this results in Ser-133 phosphorylation of the cAMP 
Responsive Elements Binding protein (CREB) and enhanced 
transcriptional activity through cAMP Responsive Elements 
(CRE), which are present in GH and PRL gene promoters; 
(5) the RET proto-oncogene is the tyrosine kinase receptor 
for the Glial cell line-Derived Neurotrophic Factor (GDNF) 
family of ligands; binding of AIP to RET prevents the for-
mation of AIP/survivin complexes (6), in the absence of 
RET, AIP binds survivin, preventing its degradation thus 
protecting cells from apoptosis. (7) Tom 20 are proteins 
involved in mitochondrial import and (8) Viral proteins 
include the Hepatitis B virus X antigen and the Epstein Barr 
Virus ( EBV )-encoded nuclear antigen-3 (EBNA-3).  See text 
for references (NB Authorization to reproduce this  fi gure 
from Jaffrain-Rea et al.  ( 2010 ) has been obtained from 
Expert Reviews in Endocrinology and Metabolism) 
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according to the biological effects of distinct 
mutations on target cells and the presence of 
genetic or environmental modi fi ers. The contrast 
between the frequent severity of the disease and its 
incomplete or low penetrance differentiates most 
 AIP mu t  kindreds from MEN1 kindreds and should 
be taken into account for genetic counselling 
(Jaffrain-Rea et al.  2010 ) (Fig.  21.1 ). 
 Lessons from an AIP +/− Mice Model 
 The homozygous  AIP  −/−  knockout mice model 
reported by Lin et al.  ( 2007 ) displayed severe 
developmental abnormalities and embryonic 
lethality but no recognized pituitary phenotype. 
However, the pituitary gland was not studied. 
Recently, the heterozygous  AIP +/− mice model 
developed by Raitila et al.  ( 2010 ) proved to 
develop pituitary tumors with a full penetrance. 
Such a high penetrance might be partially 
explained by the spontaneous development of 
PA in this strain of mice, since up to 40% of 
wild-type controls were also affected – mostly by 
prolactinomas – between 6 and 18 months-old. 
In contrast, 100% of  AIP mu t  animals developed 
PA – 80% somatotropinomas – from 3 to 15 
months-old, with  AIP mu t  tumors being more 
aggressive and displaying a higher proliferative 
index than spontaneous tumors. These observa-
tions clearly support the tumor suppressing role 
of AIP in somatotrophs. 
 AIP, AHR and Other AIP-Related 
Proteins in the Pathogenesis 
of Pituitary Adenomas 
 Pituitary Expression of AIP 
 The interest towards the pituitary expression of 
AIP in the normal pituitary and its biological 
signi fi cance was born with its identi fi cation as a 
new pituitary tumor suppressing gene. Studies 
by Leontiou et al.  ( 2008 ) and Jaffrain-Rea et al. 
 ( 2009 ) have clearly shown an abundant expres-
sion of AIP in normal human pituitaries and 
indicated a topographic distribution largely over-
lapping that of GH-secreting cells, other AIP-
expressing cells being mostly lactotrophs. This 
phenotypic characterization was con fi rmed by 
ultrastructural studies which also localized AIP 
in hormone-secreting granules. In contrast with 
the restricted expression of AIP in the normal 
pituitary, both groups have observed a potential, 
though heterogeneous, expression of AIP in all 
PA phenotypes. According to Real-Time RT-PCR 
analysis and immunohistochemical studies, the 
highest levels of AIP expression were observed 
in somatotropinomas, but also, unexpectedly, in 
non-functioning pituitary adenomas (NFPA). 
In  AIP  mut  tumors, AIP expression was typically 
down-regulated, due to hemizigosity, but the 
mutated protein could be readily detected in 
most cases. Intriguingly, we also noticed that 
AIP down-regulation was frequent in aggressive 
somatotropinomas, regardless of  AIP mutations, 
and in the vast majority of prolactinomas, includ-
ing microprolactinomas. These  fi ndings support 
a potential role for AIP in the pathogenesis of 
sporadic somatotropinomas, and suggest that, in 
addition to germline mutati ons, currently unrec-
ognized mechanisms are responsible for AIP 
loss of expression in tumorous somatotrophs and 
lactotrophs. 
 The AIP Protein: From Structure 
to Function 
 The AIP protein, also known as ARA9/XAP2, is 
composed in humans of 330 aminoacids, with a 
high degree of conservation among species. Its 
expression starts in the embryo, and is nearly 
ubiquitous in the adult. From a functional point 
of view, its N-terminal half contains a FK506 
binding peptidyl-prolyl cis-trans isomerase (PPI) 
domain sharing elevated homology with immu-
nophilins of the FKBP52 class, whereas its 
C-terminal half contains three tetratricopeptide 
(TPR) domains, typically involved in protein-
protein interactions, and a C-terminal  a -helix 
(Carver et al.  1998 ) . Therefore, AIP looks like a 
complex regulatory protein, able to indirectly 
modulate a number of cellular pathways and 
functions. Already characterized protein partners 
of AIP include: (1) the Aryl Hydrocarbon 
Receptor (AhR, also known as the “dioxin recep-
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tor”) itself, a member of the bHLH/PAS (basic 
Helix-Loop-Helix/Per-Arnt-Sim) family of tran-
scription factors involved in cell response to 
polycyclic aromatic hydrocarbons but also in 
developmental processes and the regulation of 
cell cycle and differentiation, which unliganded 
form is stabilized in the cytoplasm in a multi-
meric AIP/AhR/Hsp90 complex; (2) the phos-
phodiesterases PDE4A5 and PDE2A, which 
are implicated in the cAMP signaling pathway; 
(3) the anti-apoptotic factor survivin and Ret, 
which prevents the formation of the AIP/survivin 
complex; (4) members of the steroid receptor 
superfamily such as PPAR- a , the  b -thyroid hor-
mone receptor 1 (TR b 1) and the glucocorticoid 
receptor; (5) additional proteins among which 
viral proteins and proteins involved in mitochon-
drial import (Oz fi rat and Korbonits  2010 and 
Jaffrain-Rea et al.  2010a ) . 
 The molecular pathways involved in AIP-
related pathogenesis have not been elucidated 
yet, but  in vitro experiments on the rat lactosoma-
totroph cell line GH 3 have clearly shown that 
overexpression of the wild-type  AIP gene reduces 
its proliferation rate, whereas the transfection of 
some  AIP  mut  genes inhibits this effect (Leontiou 
et al.  2008 ) and  AIP gene silencing had a pro-
proliferative effect (Heliövaara et al.  2009 ) . This 
is in agreement with the proliferative index 
observed in the  AIP  +/−  mice model cited hitherto 
(Raitila et al.  2010 ) . Because most  AIP mutations 
described so far may theoretically disrupt one or 
more functional interactions of AIP, we will now 
analyse which mechanisms could be the most 
attractive for pituitary tumorigenesis. 
 AIP and the Regulation of AHR 
Signalling 
 The best characterized function of AIP is to inter-
act with the AhR/dioxin receptor and contributes 
to its stabilization in a AIP/AhR/hsp90/p23 cyto-
plasmic complex. The classical pathway for AhR 
activation is initiated by the binding of exogenous 
ligands such as dioxin and aromatic hydrocar-
bons. This stimulates the nuclear translocation of 
AhR and its heterodimerization with the closely 
related ARNT (AhR Nuclear Translocator, also 
known as the Hypoxia-Inducible Factor 1 b , 
HIF1 b ). The AhR/ARNT complex then binds 
DNA consensus sequences known as XRE
(xenobiotic-) /DRE(dioxin-response elements) 
localized in the promoter of responsive genes, 
recruits coactivator molecules and stimulates the 
transcription of a number of genes, including 
detoxifying enzymes which mediate the toxic 
response and genes involved in cell cycle control. 
The activated AhR is then quickly exported to the 
cytosol where it is degradated by the proteasome, 
hence preventing constitutive activity. There is 
also accumulating evidence for nucleo-cytoplasmic 
shuttling of AhR in the absence of exogenous 
ligands. Such  fi ndings, together with the ances-
tral and highly conserved expression of AhR, and 
the developmental abnormalities and diseases 
observed in the AhR null mice, clearly point to 
endogenous functions, which likely represent the 
key role of AhR during evolution and are sup-
ported by the report of an increasing number of 
potential endogenous activators of AhR. The 
complex control of gene expression by AhR and 
the potential crosstalk of AhR-related pathways 
with other signalling pathways, including hor-
mone signalling, have been recently reviewed in 
details by Beischlag et al.  ( 2008 ) and Puga et al. 
 ( 2009 ) , respectively. We will therefore attempt to 
evaluate their potential relevance to pituitary 
tumorigenesis. 
 AHR and the Pituitary Gland 
 The AhR is widely expressed in endocrine tis-
sues, and its activation by exogenous dioxin-
related compounds has been shown to potentially 
modulate pituitary function. Elango et al.  ( 2006 ) 
reported that  in vitro exposure of rainbow trout 
pituitary cells to 2,3,7,8 tetrachlorodibenzo- p -
dioxin (TCDD) induces GH and prolactin (PRL) 
secretion, in part through AhR-mediated tran-
scriptional effects. Dioxin is also able to inter-
fere with both the hypothalamic-pituitary-adrenal 
and hypothalamic-pituitary-gonadal axis, but no 
clear-cut effect has been reported on normal 
adult corticotrophs or gonadotrophs  in vitro . 
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Surprisingly, dioxin exposure appears to reduce 
the incidence of spontaneous PA in the rat, but 
not in humans. 
 We have recently studied the expression of 
AhR in the normal human pituitary and in a sub-
set of human PA, including  AIP mut tumors, by 
Real-Time RT-PCR and immunohistochemistry 
(Jaffrain-Rea et al.  2009 ) . The expression of AhR 
was lower than observed for AIP, but tended to 
have a broader phenotypic distribution. We used 
two anti-AhR antibodies, one monoclonal directed 
against a N-terminal epitope of the protein, near 
the DNA-binding domain, and one polyclonal 
against the C-terminal half of the protein, respec-
tively. The  fi rst one showed a selective cytoplas-
mic immunostaining, which was signi fi cantly 
correlated with AIP expression, thereby support-
ing a role for AIP in the stabilization of AhR in 
the pituitary as reported in other tissues. 
Accordingly, cytoplasmic AhR expression was 
down-regulated in most  AIP  mut  PA and in  non-
AIP  mut  PA displaying a low AIP expression. 
Nuclear immunostaining was best revealed by 
the C-terminal antibody, possibly due to epitope 
masquerading using the N-terminal antibody, but 
restricted to a minority of cases – mostly soma-
totropinomas and some AIP-expressing NFPA-. 
In contrast with Heliovaara et al.  ( 2009 ) who 
reported nuclear AhR immunostaining in a sub-
set of  AIP  mut  PA, this was not observed in our 
series. These data suggest that AhR signalling 
might be differentially regulated in PA, depend-
ing on phenotype and AIP status. 
 Down-regulation of the AhR partner ARNT 
has been observed in ~50% of the human  AIP  mut  
PA studied by Heliovaara et al.  ( 2009 ) , and fur-
ther supported by studies in the  AIP  +/−  mice 
model developed by the same group (Raitila et al. 
 2010 ) . In this model, AIP expression was lost in 
almost all PA arising in  AIP  +/−  animals, due to 
LOH, and accompanied by loss of ARNT and/or 
its homologue ARNT2 in most cases (>90%). 
In contrast, AIP, ARNT and ARNT2 expression 
were maintained in all PA arising in the control 
mice. The biological signi fi cance of these  fi ndings 
remains unclear, since AhR expression was not 
reported in this model and an alternative partner 
of ARNT/ARNT2, the Hypoxia-Inducible Factor 
HIF1 a , was similarly expressed in  AIP -pro fi cient 
and  AIP -de fi cient PA, respectively. 
 AHR, the Cell Cycle and Tumorigenesis 
 Molecular mechanisms linking AhR to cell cycle 
regulation are of great pathological interest since 
AhR has been potentially implicated in cancer in 
several ways: (1) dioxin is a well-recognized car-
cinogen – with no speci fi c site of tumor induction 
– and most effects of dioxin and related compounds 
are mediated by AhR; (2) overexpression of AhR 
has been reported in human cancers, such as 
breast cancer and melanoma. On the other hand, 
AhR down- regulation has also been observed in 
a minority of tumors (i.e. acute lymphocytic leu-
kaemia) and exogenous stimulation of AhR has 
variable effects on cell proliferation. Indeed, in 
most cases a growth-suppressing effect of exog-
enous AhR activation is observed, and this is 
mediated by an induction of the CDKI p27 Kip1 
through AhR/ARNT binding on a DRE element . 
ARNT is absolutely required for this effect, and 
pRB has also been proposed as a co-activator. 
The interaction of AhR with pRb has been well 
documented: AhR interacts with hypophospho-
rylated pRb through at least two distinct pRb-
binding domains and synergizes with pRb to 
repress the transcription of E2F-induced genes 
such as cyclin E, cdk2, DNA polymerase  a and 
S-phase enzymes. Thus, AhR activation may 
arrest the cell cycle in G1/S. Because this effect 
requires pRb, it is lost in abnormal pRb-de fi cient 
cells. On the other hand, because E2F-1 is a pro-
apoptotic member of the E2F family, which is able 
to arrest cells in G2/M, AhR can also inhibit the 
pro-apoptotic response by binding E2F-1 and 
promote cell survival. This occurs in the presence 
of DNA damage, when E2F-1 is stabilized in its 
active for by ATM/ATR and Chk2 phosphoryla-
tion. This dual control on the cell cycle has been 
reported by Marlowe and Puga  ( 2005 ) as the 
“ying-yang” effect of AhR. There is also consid-
erable evidence that endogenous AhR has a pro-
proliferative potential. A possible explanation to 
this phenomenon has been provided recently on 
breast cancer cell lines, showing that endogenous 
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AhR forms a complex with cyclinD/cdk4 enhanc-
ing pRb phosphorylation, whereas stimulation by 
exogenous ligands disrupts such interaction and 
promotes pRb effects on the repression of E2F-
induced genes ( Barhoover et al.  2010 ). Therefore, 
it has become more and more evident that the 
 fi nal effect of AhR activation on cell growth, 
differentiation and apoptosis depends on a series 
of factors, including the presence or the absence 
of exogenous ligands, and cell phenotype, status 
and environment (Puga et al.  2009 ) . On the other 
hand, the induction of early response oncogenes 
by dioxin and related compounds, which partici-
pate in their tumorigenic effects, does not appear 
to be dependent on AhR/ARNT transcription. To 
summarize, AhR generally induces growth arrest 
in the presence of exogenous ligands, whereas in 
the absence of exogenous ligands, it may exert an 
anti-apoptotic, prosurvival effect. 
 It is worth noting that the activation of AhR is 
also regulated by phosphorylation in its C-terminal 
half, which provides a further level of crosstalk 
between AhR and extracellular signalling linked 
to cell growth, differentiation and apoptosis. This 
phenomenon has been recently reviewed by 
Henkovà et al.  ( 2008 ) . Brie fl y, mitogen-activated 
protein kinases (MAPKs), which can be activated 
by a variety of growth factors, cytokines, and cel-
lular stressful events including genotoxic and 
oxidative stress, are able to differentially modu-
late AhR subcellular localization, transcriptional 
activity and protein stability. Conversely, exoge-
nous ligands of AhR have also been found to acti-
vate MAPKs. Whether the interplay between 
MAPKs and AhR signalling is relevant to pitu-
itary tumorigenesis warrants further investiga-
tion, since MAPKs – especially the Extracellular 
Regulated Kinases ERK1/2, which can directly 
associate with AhR – have been involved in pitu-
itary tumorigenesis (Cakir and Grossman  2009 ) . 
 Finally, it should be noticed that the transcrip-
tion factors RelA and RelB, which are involved 
in the in fl ammatory response but also in the regu-
lation of cell survival and apoptosis induced by 
cytokines, are also able to dimerize with AhR, 
and cross-talk has been established between 
exogenous AhR activation and NFkB signalling 
(Beischlag et al.  2008 ) . 
 AHR, AIP and the Modulation of Nuclear 
Endocrine Signalling 
 Among the multiple cross-talks involving AhR 
signalling, is able the best characterized is endo-
crine disruption, which is believed to account for 
the reported effects of dioxin and related com-
pounds on thyroid function, sexual development 
and function, fertility, and some endocrine-related 
cancers such as testicular cancer. Several lines of 
evidence suggest that AhR is able to mediate off-
target or non-DNA binding dependent transcrip-
tion. The potential role of AIP in the endocrine 
disrupting effects of AhR is unclear, but AIP 
itself has been reported to interfere with steroid 
receptor activity – i.e. inhibition of glucocorti-
coid receptor activity through direct AIP/GR/
Hsp90 interaction (Laenger  et al.  2009 ) -, further 
enhancing the complexity of endocrine modula-
tion by the AIP/AhR system. 
 AHR and Endocrine Disruption 
 Dioxin is a major endocrine disruptor. It reduces 
estrogen signalling in many ways including (1) 
increased estrogen metabolism through the 
CYP1a/b and CYP19/aromatase enzymes, (2) 
increased ER a degradation, (3) reduced ER tran-
scriptional activity due to DRE upstream to ERE 
in target gene promoters, direct competition on 
ERE binding or for the recruitment of common 
co-activators (squelching). Also, both AhR and 
ARNT are able to directly interact with the ER , 
and ER may be recruited on active DRE elements 
and enhance AhR transcription, whereas ER sig-
nalling in itself is reduced (Beischlag et al.  2008 ) . 
The endocrine disrupting effects of dioxin-related 
compounds as industrial pollutants have been 
widely studied in  fi sh species because of their 
impact on sexual development and fertility. 
Elango et al.  ( 2006 ) have observed, in the rain-
bow trout pituitary, that both estradiol and TCDD 
were able to stimulate GH and PRL transcription 
in a dose-dependent manner. The estrogenic 
effects of TCDD were observed only in the 
absence of E2 and strongly reduced by the addi-
tion of an AhR antagonist. This can be explained 
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by binding of the activated AhR/ARNT to the 
unliganded ER a / b , which results in the recruit-
ment of unliganded ER and the co-activator 
p300 to ERE, with  subsequent activation of gene 
transcription and oestrogenic effects. In contrast, 
in the presence of both TCDD and E 2 , PRL tran-
scription was lower than in controls, con fi rming 
endocrine disruption (transrepression). Additional 
nuclear partners of AhR have been reported, 
including the androgen receptor and TR, poten-
tially interfering with endocrine signalling. 
 The observation that AIP  mut  PA are more fre-
quent and more severe in male patients – gigan-
tism and resistant macroprolactinomas have been 
reported in males – is intriguing and yet unex-
plained. Studies from our laboratory have shown 
that PA express sex steroid hormones receptors 
with a differential pattern according to phenotype 
and patient’s gender and gonadal function 
(Jaffrain-Rea et al.  1996 ) , and that sex steroids 
are able to modulate their proliferation  in vitro 
accordingly (Caronti et al.  1995 ) . In particular, 
ER expression was higher in male prolactinomas 
and 17 b -estradiol had a proliferative effect on 
most ER-expressing PA. It is tempting to hypoth-
esize that abnormal crosstalk between sex ste-
roids and AhR signalling in AIP-de fi cient cells 
might contribute to gender-related variations in 
tumor phenotype. 
 Interactions of AIP and AHR with PPAR a 
 AIP is able to interact with PPAR a which, unlike 
other type II steroid receptors, may be present in 
a latent form and form a complex with AIP and 
hsp90 (Sumanasekera et al.  2003 ) . Like AhR, 
PPAR a can be activated by endogenous or exog-
enous ligands, and exerts complex transcriptional 
effects which are highly dependent on cell type 
and environment. The transcriptional effects of 
PPAR agonists are mediated through PPAR/RXR 
heterodimers binding to the consensus sequences 
PPREs. A stimulating effect of PPAR a agonists 
on PRL transcription and secretion has been 
reported in GH 4 C 1 cells, which is believed to be 
indirect and dependent on Pit-1 activation and 
recruitment of co-activators (Tolon et al.  1998 ) . 
Interestingly, AIP inhibits the transcriptional 
activity of PPAR a , suggesting that loss of AIP 
function or expression in Pit-1-dependent cells 
may contribute to AIP-related pathogenesis. 
In addition, PPARs are affected by dioxin and 
related compounds in an AhR-dependent man-
ner, and PPAR a agonists may either potentiate 
or repress CYP1A genes transcription according 
to the cellular context (Beischlag et al.  2008 ) . 
The potential effects of the AhR alterations 
reported in pituitary cells on PPAR a signalling 
are unknown. 
 AIP, AHR and the Modulation 
of the cAMP Pathway 
 The cAMP-protein kinase A (PKA) pathway is 
essential for somatotrophs and lactotroph cells. 
In somatotrophs, it stimulates hormone secretion 
and cell proliferation and is positively and nega-
tively regulated by the hypothalamic Growth-
Hormone Releasing Hormone (GHRH) and 
somatostatin (SMS), respectively, whereas lac-
totrophs are under physiological inhibition by 
hypothalamic dopaminergic signalling. Consti-
tutive activation of the cAMP pathway has been 
involved in the pathogenesis of sporadic pituitary 
tumorigenesis and inherited forms of somatolac-
totroph adenomas and/or hyperplasia in the 
setting of Carney complex or McCune Albright 
syndrome (Boikos and Stratakis  2007 ) . Transgenic 
GHRH mice develop somatotroph hyperplasia 
and adenomas, and in humans activating muta-
tions of the Gsalpha subunit gene (GNAS1) are 
the most common somatic mutations observed 
in somatotropinomas. Conversely, somatostatin 
analogues and dopamine-agonists are widely 
used in the pharmacological treatment of human 
somatotropinomas and prolactinomas, respec-
tively. Upon ligand activation, speci fi c receptors 
for these drugs – the somatostatin receptors SSTR 
1,2,3,5 and the dopamine-agonist receptor D2R 
– inhibit the adenylate cyclase/cAMP/ PKA path-
way, resulting in reduced hormone secretion and, 
to a variable extent, tumor shrinkage. Whether 
the unusual rate of pharmacological resistance 
observed in  AIP  mut  PA is due to some alteration in 
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cAMP-related pathways remains to be de fi ned, 
but both AIP and AhR have been reported to 
modulate cAMP signalling in non pituitary mod-
els and some  fi ndings could be potentially 
extended to pituitary cells. 
 On one hand, cAMP is considered as a non-
ligand endogenous activator of AhR, able to 
stimulate its translocation to the nucleus simi-
larly to dioxin, although in this case nuclear AhR 
does not appear to dimerize with ARNT or 
induce CYP1A transcription, but rather forms a 
complex with yet unidenti fi ed proteins. Thus, 
cAMP itself or some event downstream cAMP 
may modulate the response to AhR and act as a 
repressor rather than an activator of classical 
AhR-dependent gene expression. On the other 
hand, AIP has been shown to interact with some 
phosphodiesterases (PDEs), which inactivate 
cyclic nucleotides, and this may modulate cAMP 
concentration and/or AhR nuclear translocation 
and transcriptional activity. Such mechanisms 
have been recently reviewed by de Oliveira and 
Smolenski  ( 2009 ) . Brie fl y, a direct interaction of 
AIP with the isoforms PDE4A5 and PDE2 has 
been demonstrated, which is mediated by its 
TPR domains. PDE4 phosphodiesterases are 
involved in cAMP degradation and induced by 
PKA (and ERK). Binding to AIP appears speci fi c 
of the PDE4A5 isoform, and results in a dramatic 
decrease in its enzymatic activity. As shown by 
Leontiou et al.  ( 2008 ) and further supported by 
work from the same group (Igreja et al.  2010 ) a 
number of germline AIP mutations have proven 
to lose the ability to interact with PDE4A5. 
Intriguingly, disruption of AIP/PDE4A5 interac-
tion should lead to reduced intracellular cAMP 
concentrations. PDE2 is induced by cGMP and 
involved in the regulation of cAMP and cGMP 
concentrations. Interaction with AIP has no 
effect on its enzymatic activity, but PDE2 inhib-
its nuclear AhR translocation, likely as a result 
of local regulation of cAMP concentration. The 
effects of  AIP mutations on AIP/PDE2 interac-
tion have not been determined yet. Potential 
alterations in the cAMP pathway in the presence 
of abnormal AIP or AhR expression and func-
tion should be further investigated. 
 AIP and the RET/Survivin Interaction 
 It was recently reported by Vargiolu et al.  ( 2009 ) 
that AIP is able to interact with survivin, an anti-
apoptotic protein, and the tyrosine kinase recep-
tor Ret. In this model, interaction of AIP with Ret 
prevents the stabilization of survivin by AIP. This 
represents an interesting potential link between 
AIP and cell survival, and an anti-apoptotic role 
of AIP may be hypothesized for example in 
NFPA expressing AIP. The Ret receptor is acti-
vated by the Glial-Derived Neurotrophic Factor 
(GDNF) forming a complex with the GDNF-
Receptor  a (GFR a 1). Japon et al.  ( 2002 ) have 
previously shown that Ret and its 2-ligand sys-
tem GDNF and GFR a 1 are expressed in the nor-
mal pituitary, essentially by somatotrophs, and 
invariably detected in somatotropinomas. The 
biological function of Ret in somatotrophs has 
then been investigated by the same group, using 
 in vitro experiments and a Ret knock-out mice 
model, clearly showing that Ret was able to 
regulate the number of somatotroph cells through 
a Pit-1/p53/apoptotic pathway (Cañibano et al. 
 2007 ) . Although Vargiolu et al.  ( 2009 ) have 
tested the effects of some missense AIP muta-
tions on RET binding and found no noticeable 
change, truncating mutations were not studied. 
It is tempting to hypothesize that some AIP muta-
tions may disrupt its interaction with Ret, thereby 
allowing AIP to promote pituitary cell survival 
through survivin stabilization and/or abnormal 
Ret signalling. 
 Conclusion and Future Perspectives 
 The discovery of AIP as a predisposing gene 
for pituitary adenomas has opened a new  fi eld 
in the study of pituitary tumorigenesis, offering 
a broad spectrum of potentially related abnor-
malities in molecular pathways involved in 
endocrine signalling as well as the control of 
cell proliferation and apoptosis. Some of them 
involve completely new players in pituitary 
biology – such as AhR and related molecules –, 
others are more familiar pathways – such as the 
19921 The Role of Aryl Hydrocarbon Receptor (AHR) and AHR-Interacting Protein (AIP)…
cAMP-PKA pathway – to be revised at the light 
of new potential mechanisms of crosstalk in the 
pituitary gland. At the moment, the pathogenic 
role of the best characterized AIP partner, AhR 
has not been de fi nitively proven in pituitary 
cells, and endocrine disruption and pathways 
such as PPAR and Ret signalling represent 
additional attractive candidates. The potential 
in fl uence of AIP in the pharmacological response 
to the widely used somatostatin analogues 
and dopamine-agonist drugs should be evalu-
ated and may provide new insights in the 
comprehension of pharmacological resistance 
in PA Preliminary data from our laboratory 
indicate that pre-operative treatment with SSA 
is associated with a higher AIP expression in 
sporadic, but not in AIPmut, somatotropinomas 
(Jaffrain-Rea et. al,  2010 b ). Interestingly, 
unlike the  MEN1 gene, which seems poorly 
involved in sporadic pituitary pathogenesis, 
AIP may also play a signi fi cant role in the patho-
genesis of a subset of PA, regardless of  AIP 
mutations. In addition, inherited predisposition 
linked to the  AIP gene is characterized by an 
incomplete or low penetrance, which strongly 
supports the need for additional factors to initi-
ate or promote pituitary tumorigenesis and stimu-
lates research work aimed to their identi fi cation. 
Another open issue remains the pituitary 
speci fi city of  AIP -related neoplasia, since addi-
tional tumors have been occasionally observed 
in  AIP  mut  patients, and LOH in 11q13 with loss of 
the wild-type AIP allele was recently reported 
by Toledo et al.  ( 2010 ) in an adrenocortical 
carcinoma operated on in an acromegalic patient 
with a truncating familial  AIP mutation. Because 
AIP has a rather ubiquitous expression, the 
signalling pathways which are potentially 
disrupted by  AIP mutations may be relevant 
for tumorigenesis in other tissues. The mice 
model developed by Raitila et al.  ( 2010 ) , genetic 
studies aimed at the identi fi cation of modi fi er 
loci in  AIP  mut  kindreds, new genomic and 
proteomic tools applied to  AIP  mut  tumors and 
 in vitro models, should help provide signi fi cant 
insights into AIP-related pathogenesis in a the 
next future. 
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